创伤相关静脉血栓栓塞中的血小板通量:CLOTT研究二次分析
本研究为CLOTT1多中心前瞻性队列研究的二次分析,纳入18至40岁、住院至少48小时且至少有一项VTE危险因素的创伤患者7805例,其中425例(5.4%)发生VTE。VTE组各时间点血小板计数均较低,初始血小板计数每降低10×10^9/L与VTE发生相关(OR 1.32,95%CI 1.13-1.53,p<0.01)。在129例CLOTT2患者中,VTE组血小板聚集速度在入院时对ADP刺激、48小时对凝血酶刺激及72小时总体聚集均较高,而血栓弹力图组间无差异。作者认为,探究血小板计数和功能反应可能有助于评估伤后血栓并发症。
要点
- 创伤患者入院时血小板计数每降低10×10^9/L,VTE发生风险增加(OR 1.32,95%CI 1.13-1.53,p<0.01),校正休克、损伤严重度、凝血病、性别和血制品输注后仍显著。
- VTE组血小板计数在入院时(242 vs 254,×10^9/L,p<0.01)和住院第1天(157 vs 197,×10^9/L,p<0.01)均低于非VTE组。
- 在129例CLOTT2患者中,VTE组入院时ADP刺激下血小板聚集速度更高(18.5 vs 12.8聚集单位/分钟,p<0.01)。
- VTE组凝血酶刺激下48小时血小板聚集速度更高(34.4 vs 12.3聚集单位/分钟,p<0.01),72小时总体聚集更高(曲线下面积173.2 vs 129.6,p<0.01)。
- 血栓弹力图结果在VTE组与非VTE组间无差异。
适用人群与场景
- CLOTT1:18至40岁、住院至少48小时、至少有一项VTE危险因素的创伤患者。
- CLOTT2:CLOTT1中接受血小板聚集测定和血栓弹力图检查以评估血小板功能的亚组患者。
研究设计与关键结果
- 研究类型:多中心前瞻性队列研究(CLOTT1)的预设二次分析,包含血小板功能亚组(CLOTT2)。
- CLOTT1纳入7805例患者(平均[SD]年龄29.1[6.4]岁;女性1987例[25.5%]),425例(5.4%)发生VTE。
- VTE组血小板计数较低:入院时242(234-251)vs 254(252-256),p<0.01;住院第1天157(150-164)vs 197(195-198),p<0.01;所有计数单位为×10^9/L。
- 初始血小板计数每降低10×10^9/L与VTE发生相关(OR 1.32,95%CI 1.13-1.53;p<0.01),校正休克、损伤严重度、凝血病、性别和血制品输注。
- CLOTT2的129例患者中,VTE组入院时ADP刺激下血小板聚集速度更高(18.5 vs 12.8聚集单位/分钟;p<0.01)。
- 凝血酶刺激下,VTE组48小时血小板聚集速度更高(34.4 vs 12.3聚集单位/分钟;p<0.01),72小时总体聚集更高(曲线下面积173.2 vs 129.6;p<0.01)。
- 血栓弹力图结果组间无差异。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究的二次分析;证据等级:诊断测试/标准,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,探究血小板计数和功能反应可能有助于评估伤后血栓并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Venous thromboembolism (VTE) after traumatic injury is morbid. Evaluating changes in platelets in injured patients who develop VTE could identify platelet-based strategies for management of thrombotic complications after injury.
METHODS: In a prospectively designed secondary analysis of a multicenter cohort study conducted by the Consortium of Leaders in the Study of Traumatic Thromboembolism (CLOTT1) study group, injured patients aged 18 to 40 years admitted for a minimum of 48 hours with at least one risk factor for VTE were evaluated. A subset of CLOTT1 patients had platelet aggregometry and thromboelastography performed to examine platelet function (CLOTT2). Patients who developed VTE were compared with those who did not.
RESULTS: Of 7,805 patients from CLOTT1 (mean [SD] age, 29.1 [6.4] years; 1,987 [25.5%] female), 425 (5.4%) developed VTE. Platelet count was lower at each time point for patients with VTE (admission: 242 [234-251] vs. 254 [252-256], p < 0.01; hospital day 1: 157 [150-164] vs. 197 [195-198], p < 0.01; all counts ×10 9 /L). An initial 10-point reduction in platelet count was associated with development of VTE (odds ratio, 1.32 [1.13-1.53]; p < 0.01) controlling for shock, injury severity, coagulopathy, sex, and product transfusion. When evaluating 129 CLOTT2 patients, velocity of platelet aggregation was higher on admission in the VTE group (18.5 vs. 12.8 aggregation units/min; p < 0.01) in response to adenosine diphosphate stimulation. In response to thrombin stimulation, velocity of platelet aggregation was higher at 48 hours (34.4 vs. 12.3 aggregation units/min; p < 0.01), and overall aggregation was higher in the VTE group at 72 hours (area under the curve, 173.2 vs. 129.6; p < 0.01). Thromboelastography results were not different between groups.
CONCLUSION: This study identified an association of early reduction in platelet count with the development of VTE in injured patients at risk for VTE. P2Y 1/2 and protease-activated receptor 1 receptor stimulation changes in platelet aggregation responses are altered in VTE patients. Interrogating platelet count and functional responses may be beneficial in evaluating thrombotic complications after injury.
LEVEL OF EVIDENCE: Diagnostic Test/Criteria; Level III.
参考来源
- Andraska E, Fields A, Nunez-Garcia B, et al. Platelet flux in trauma-associated venous thromboembolism: A secondary analysis of the Consortium of Leaders in the Study of Traumatic Thromboembolism (CLOTT) studies. J Trauma Acute Care Surg. 2025. PMID: 40107968. doi:10.1097/TA.0000000000004592
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。